CD1d ligands: The good, the bad, and the ugly

Journal of Immunology

Volumn 177, Issue 2, 2006, Pages 769-775

  Brutkiewicz, Randy R ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GLYCOLIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHOSPHOLIPID;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CANCER; IMMUNOPOTENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; NATURAL KILLER T CELL; PRIORITY JOURNAL; REVIEW; SPONGE (PORIFERA); T LYMPHOCYTE; VIRUS INFECTION;

EID: 33745838249     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.2.769     Document Type: Review

References (94)

1. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16: 323-358.
2. Simister, N. E., and K. E. Mostov. 1989. An Fc receptor structurally related to MHC class I antigens. Nature 337: 184-187.
3. Simister, N. E., and K. E. Mostov. 1989. Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb. Symp. Quant Biol. 54: 571-580.
4. Zhu, X., G. Meng, B. L. Dickinson, X. Li, E. Mizoguchi, L. Miao, Y. Wang, C. Robert, B. Wu, P. D. Smith, et al. 2001. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J. Immunol. 166: 3266-3276.
5. Enns, C. A. 2001. Pumping iron: the strange partnership of the hemochromatosis protein, a class I MHC homolog, with the transferrin receptor. Traffic 2: 167-174.
6. Porcelli, S. A. 1995. The CD1 family: a third lineage of antigen-presenting molecules. Adv. Immunol. 59: 1-98.
7. Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23: 877-900.
8. Moody, D. B., D. M. Zajonc, and I. A. Wilson. 2005. Anatomy of CD1-lipid antigen complexes. Nat. Rev. Immunol. 5: 387-399.
9. Castano, A. R., S. Tangri, J. E. W. Miller, H. R. Holcombe, M. R. Jackson, W. D. Huse, M. Kronenberg, and P. A. Peterson. 1995. Peptide binding and presentation by mouse CD1. Science 269: 223-226.
10. Zeng, Z., A. R. Castano, B. W. Segelke, E. A. Stura, P. A. Peterson, and I. A. Wilson. 1997. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277: 339-345.
11. Joyce, S., A. S. Woods, J. W. Yewdell, J. R. Bennink, A. D. De Silva, A. Boesteanu, S. P. Balk, R. J. Cotter, and R. R. Brutkiewicz. 1998. Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 279: 1541-1544.
12. De Silva, A. D., J. J. Park, N. Matsuki, A. K. Stanic, R. R. Brutkiewicz, M. E. Medof, and S. Joyce. 2002. Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J. Immunol. 168: 723-733.
13. Park, J. J., S. J. Kang, A. D. De Silva, A. K. Stanic, G. Casorati, D. L. Hachey, P. Cresswell, and S. Joyce. 2004. Lipid-protein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. Proc. Natl. Acad. Sci. USA 101: 1022-1026.
14. Giabbai, B., S. Sidobre, M. D. Crispin, Y. Sanchez-Ruiz, A. Bachi, M. Kronenberg, I. A. Wilson, and M. Degano. 2005. Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: a molecular basis for NKT cell activation. J. Immunol. 175: 977-984.
15. Gumperz, J. E., C. Roy, A. Makowska, D. Lum, M. Sugita, T. Podrebarac, Y. Koezuka, S. A. Porcelli, S. Cardell, M. B. Brenner, and S. M. Behar. 2000. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12: 211-221.
16. Roberts, T. J., V. Sriram, P. M. Spence, M. Gui, K. Hayakawa, I. Bacik, J. R. Bennink, J. W. Yewdell, and R. R. Brutkiewicz. 2002. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J. Immunol. 168: 5409-5414.
17. Porcelli, S. A., and R. L. Modlin. 1999. The CD1 System: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17: 297-329.
18. Jayawardena-Wolf, J., and A. Bendelac. 2001. CD1 and lipid antigens: intracellular pathways for antigen presentation. Curr. Opin. Immunol. 13: 109-113.
19. Watts, C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15: 821-850.
20. Kang, S. J., and P. Cresswell. 2004. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 5: 175-181.
21. Zhou, D., C. Cantu III, Y. Sagiv, N. Schrantz, A. B. Kulkarni, X. Qi, D. J. Mahuran, C. R. Morales, G. A. Grabowski, K. Benlagha, et al. 2004. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303: 523-527.
22. Zhou, D., J. Mattner, C. Cantu III, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y. P. Wu, T. Yamashita, et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789.
23. + targets. J. Immunol. 160: 3681-3688.
24. Chiu, Y. H., J. Jayawardena, A. Weiss, D. Lee, S. H. Park, A. Dautry-Varsat, and A. Bendelac. 1999. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J. Exp. Med. 189: 103-110.
25. Jayawardena-Wolf, J., K. Benlagha, Y. H. Chiu, R. Mehr, and A. Bendelac. 2001. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 15: 897-908.
26. Roberts, T. J., Y. Lin, P. M. Spence, L. Van Kaer, and R. R. Brutkiewicz. 2004. CD1d1-dependent control of the magnitude of an acute antiviral immune response. J. Immunol. 172: 3454-3461.
27. Shamshiev, A., A. Donda, I. Carena, L. Moti, L. Kappos, and G. De Libero. 1999. Self glycolipids as T cell autoantigens. Eur. J. Immunol. 29: 1667-1675.
28. Shamshiev, A., H. J. Gober, A. Donda, Z. Mazorra, L. Mori, and G. De Libero. 2002. Presentation of the same glycolipid by different CD1 molecules. J. Exp. Med. 195: 1013-1021.
29. Jahng, A., I. Maricic, C. Aguilera, S. Cardell, R. C. Halder, and V. Kumar. 2004. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199: 947-957.
30. Zajonc, D. M., I. Maricic, D. Wu, R. Halder, K. Roy, C. H. Wong, V. Kumar, and I. A. Wilson. 2005. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202: 1517-1526.
31. Wu, D. Y., N. H. Segal, S. Sidobre, M. Kronenberg, and P. B. Chapman. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198: 173-181.
32. Rauch, J., J. Gumperz, C. Robinson, M. Skold, C. Roy, D. C. Young, M. Lafleur, D. B. Moody, M. B. Brenner, C. E. Costello, and S. M. Behar. 2003. Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J. Biol. Chem. 278: 47508-47515.
33. Young, W. W., Jr., Y. Tamura, H. S. Johnson, and D. A. Miller. 1983. Decreased glycolipid antigen expression in lymphoma cell variants escaping from anti-glycolipid serotherapy. J. Exp. Med. 157: 24-33.
34. Young, W. W., Jr., C. A. Borgman, and D. M. Wolock. 1986. Modes of shedding of glycosphingolipids from mouse lymphoma cells. J. Biol. Chem. 261: 2279-2283.
35. + T cell lymphoma by natural killer T (NKT) cells. Proc. Natl. Acad. Sci. USA 99: 8197-8202.
36. Morita, M., K. Motoki, K. Akimoto, T. Natoti, T. Sakai, E. Sawa, K. Yamaji, Y. Koezuka, E. Kobayashi, and H. Fukushima. 1995. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 38: 2176-2187.
37. α14 NKT cells by glycosylceramides. Science 278: 1626-1629.
38. Wilson, M. T., C. Johansson, D. Olivares-Villagomez, A. K. Singh, A. K. Stanic, C. R. Wang, S. Joyce, M. J. Wick, and L. Van Kaer. 2003. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. USA 100: 10913-10918.
39. Crowe, N. Y., A. P. Uldrich, K. Kyparissoudis, K. J. Hammond, Y. Hayakawa, S. Sidobre, R. Keating, M. Kronenberg, M. J. Smyth, and D. I. Godfrey. 2003. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J. Immunol. 171: 4020-4027.
40. Harada, M., K. Seino, H. Wakao, S. Sakata, Y. Ishizuka, T. Ito, S. Kojo, T. Nakayama, and M. Taniguchi. 2004. Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int. Immunol. 16: 241-247.
41. + T cells upon NK T or T cell activation. J. Immunol. 165: 4305-4311.
42. Hayakawa, Y., K. Takeda, H. Yagita, S. Kakuta, Y. Iwakura, L. Van Kaer, I. Saiki, and K. Okumura. 2001. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur. J. Immunol. 31: 1720-1727.
43. Leire-De-Moraes, M. C., A. Herbelin, C. Gouarin, Y. Koezuka, E. Schneider, and M. Dy. 2000. Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes. J. Immunol. 165: 4367-4371.
44. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C. R. Wang, Y. Koezuka, and M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers, J. Exp. Med. 192: 741-754.
45. Nakagawa, R., I. Nagafune, Y. Tazunoki, H. Ehara, H. Tomura, R. Iijima, K. Motoki, M. Kamishohara, and S. Seki. 2001. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α- galactosylceramide in mice. J. Immunol. 166: 6578-6584.
46. Osman, Y., T. Kawamura, T. Naito, K. Takeda, L. Van Kaer, K. Okumura, and T. Abo. 2000. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30: 1919-1928.
47. Brutkiewicz, R. R., and V. Sriram. 2002. Natural killer T (NKT) cells and their role in antitumor immunity. Crit. Rev. Oncol. Hematol. 41: 287-298.
48. Burdin, N., L. Brossay, M. Degano, H. Iijima, M. Gui, I. A. Wilson, and M. Kronenberg. 2000. Structural requirements for antigen presentation by mouse CD1. Proc. Natl. Acad. Sci. USA 97: 10156-10161.
49. Hammond, K. J., and D. I. Godfrey. 2002. NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens 59: 353-363.
50. Matsuda, J. L., L. Gapin, J. L. Baron, S. Sidobre, D. B. Stetson, M. Mohrs, R. M. Locksley, and M. Kronenberg. 2003. Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl. Acad. Sci. USA 100: 8395-8400.
51. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 413: 531-534.
52. Yu, K. O., J. S. Im, A. Molano, Y. Dutronc, P. A. Illarionov, C. Forestier, N. Fujiwara, I. Arias, S. Miyake, T. Yamamura, et al. 2005. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl. Acad. Sci. USA 102: 3383-3388.
53. Gonzalez-Aseguinolaza, G., C. de Oliveira, M. Tomaska, S. Hong, O. Bruna-Romero, T. Nakayama, M. Taniguchi, A. Bendelac, L. Van Kaer, Y. Koezuka, and M. Tsuji. 2000. α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA 97: 8461-8466.
54. Gonzalez-Aseguinolaza, G., L. Van Kaer, C. C. Bergmann, J. M. Wilson, J. Schmieg, M. Kronenberg, T. Nakayama, M. Taniguchi, Y. Koezuka, and M. Tsuji. 2002. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624.
55. Schmieg, J., G. Yang, R. W. Franck, N. Van Rooijen, and M. Tsuji. 2005. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. USA 102: 1127-1132.
56. Schmieg, J., G. Yang, R. W. Frank, and M. Tsuji. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198: 1631-1641.
57. Yang, G., J. Schmieg, M. Tsuji, and R. W. Franck. 2004. The C-glycoside analogue of the immunostimulant α-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. Angew. Chem. Int. Ed. Engl. 43: 3818-3822.
58. Exley, M. A., N. J. Bigley, O. Cheng, S. M. Tahir, S. T. Smiley, Q. L. Carter, H. F. Stills, M. J. Grusby, Y. Koezuka, M. Taniguchi, and S. P. Balk. 2001. CD1d-reactive T cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J. Leukocyte Biol. 69: 713-718.
59. Kakimi, K., L. G. Guidotti, Y. Koezuka, and F. V. Chisari. 2000. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192: 921-930.
60. Ko, S. Y., H. J. Ko, W. S. Chang, S. H. Park, M. N. Kweon, and C. Y. Kang. 2005. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175: 3309-3317.
61. Van Dommelen, S. L., H. A. Tabarias, M. J. Smyth, and M. A. Degli-Esposti. 2003. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J. Virol. 77: 1877-1884.
62. Bilenki, L., S. Wang, J. Yang, Y. Fan, A. G. Joyce, and X. Yang. 2005. NK T cell activation promotes Chlamydia trachomatis infection in vivo. J. Immunol. 175: 3197-3206.
63. Chackerian, A., J. Alt, V. Pereta, and S. M. Behar. 2002. Activation of NKT cells protects mice from tuberculosis. Infect. Immun. 70: 6302-6309.
64. Gansert, J. L., V. Kiessler, M. Engele, F. Wittke, M. Rollinghoff, A. M. Krensky, S. A. Porcelli, R. L. Modlin, and S. Stenger. 2003. Human NKT cells express granulysin and exhibit antimycobacterial activity. J. Immunol. 170: 3154-3161.
65. + natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur. J. Immunol. 33: 3322-3330.
66. Minagawa, S., C. Ohyama, S. Hatakeyama, N. Tsuchiya, T. Kato, and T. Habuchi. 2005. Activation of natural killer T cells by α- galactosylceramide mediates clearance of bacteria in murine urinary tract infection. J. Urol. 173: 2171-2174.
67. Nieuwenhuis, E. E., T. Matsumoto, M. Exley, R. A. Schleipman, J. Glickman, D. T. Bailey, N. Corazza, S. P. Colgan, A. B. Onderdonk, and R. S. Blumberg. 2002. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat. Med. 8: 588-593.
68. + natural killer T cells by α-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69: 213-220.
69. Ronet, C., S. Darche, M. Leite de Moraes, S. Miyake, T. Yamamura, J. A. Louis, L. H. Kasper, and D. Buzoni-Gatel. 2005. NKT cells are critical for the initiation of an inflammatory bowel response against Toxoplasma gondii. J. Immunol. 175: 899-908.
70. Procopio, D. O., I. C. Almeida, A. C. Torrecilhas, J. E. Cardoso, L. Teyton, L. R. Travassos, A. Bendelac, and R. T. Gazzinelli. 2002. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. J. Immunol. 169: 3926-3933.
71. Duthie, M. S., and S. J. Kahn. 2002. Treatment with α- galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive. J. Immunol. 168: 5778-5785.
72. Miyahira, Y., M. Katae, K. Takeda, H. Yagita, K. Okumura, S. Kobayashi, T. Takeuchi, T. Kamiyama, Y. Fukuchi, and T. Aoki. 2003. Activation of natural killer T cells by α-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi. Infect. Immun. 71: 1234-1241.
73. Ortaldo, J. R., H. A. Young, R. T. Winkler-Pickett, E. W. Bere, Jr., W. J. Murphy, and R. H. Wiltrout. 2004. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172: 943-953.
74. Parekh, V. V., A. K. Singh, M. T. Wilson, D. Olivares-Villagomez, J. S. Bezbradica, H. Inazawa, H. Ehara, T. Sakai, I. Serizawa, L. Wu, et al. 2004. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173: 3693-3706.
75. Carnaud, C., D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650.
76. Eberl, G., and H. R. MacDonald. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30: 985-992.
77. Mempel, M., C. Ronet, F. Suarez, M. Gilleron, G. Puzo, L. Van Kaer, A. Lehuen, P. Kourilsky, and G. Gachelin. 2002. Natural killer T cells restricted by the monomorphic MHC class 1bCD1d1 molecules behave like inflammatory cells. J. Immunol. 168: 365-371.
78. Kinjo, Y., D. Wu, G. Kim, G. W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C. H. Wong, and M. Kronenberg. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520-525.
79. Mattner, J., K. L. Debord, N. Ismail, R. D. Goff, C. Cantu III, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529.
80. Sriram, V., W. Du, J. Gervay-Hague, and R. R. Brutkiewicz. 2005. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35: 1692-1701.
81. Wu, D., G. W. Xing, M. A. Poles, A. Horowitz, Y. Kinjo, B. Sullivan, V. Bodmer-Narkevitch, O. Plettenburg, M. Kronenberg, M. Tsuji, et al. 2005. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc. Natl. Acad. Sci. USA 102: 1351-1356.
82. Fischer, K., E. Scotet, M. Niemeyer, H. Koebernick, J. Zerrahn, S. Maillet, R. Hurwitz, M. Kursar, M. Bonneville, S. H. Kaufmann, and U. E. Schaible. 2004. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl. Acad. Sci. USA 101: 10685-10690.
83. Behar, S. M., C. C. Dascher, M. J. Grusby, C. R. Wang, and M. B. Brenner. 1999. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J. Exp. Med. 189: 1973-1980.
84. Sugawara, I., H. Yamada, S. Mizuno, C. Y. Li, T. Nakayama, and M. Taniguchi. 2002. Mycobacterial infection in natural killer T cell knockout mice. Tuberculosis 82: 97-104.
85. Amprey, J. L., J. S. Im, S. J. Turco, H. W. Murray, P. A. Illarionov, G. S. Besra, S. A. Porcelli, and G. F. Spath. 2004. A subset of liver NKT cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J. Exp. Med. 200: 895-904.
86. Van Rhijn, I., D. C. Young, J. S. Im, S. B. Levery, P. A. Illarionov, G. S. Besra, S. A. Porcelli, J. Gumperz, T. Y. Cheng, and D. B. Moody. 2004. CD1d-restricted T cell activation by nonlipidic small molecules. Proc. Natl. Acad. Sci. USA 101: 13578-13583.
87. Lee, D. J., A. Abeyratne, D. A. Carson, and M. Corr. 1998. Induction of an antigen-specific, CD1-restricted cytotoxic T lymphocyte response in vivo. J. Exp. Med. 187: 433-438.
88. Agea, E., A. Russano, O. Bistoni, R. Mannucci, I. Nicoletti, L. Corazzi, A. D. Postle, G. De Libero, S. A. Porcelli, and F. Spinozzi. 2005. Human CD1-restricted T cell recognition of lipids from pollens. J. Exp. Med. 202: 295-308.
89. + natural killer T cells in bronchial asthma. N. Engl. J. Med. 354: 1117-1129.
90. Chang, D. H., K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201: 1503-1517.
91. Giaccone, G., C. J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. Von Blomberg, R. J. Scheper, H. J. Van Der Vliet, A. J. Van Den Eertwegh, et al. 2002. A phase I study of the natural killer T cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8: 3702-3709.
92. Ishikawa, A., S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa. 2005. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11: 1910-1917.
93. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389.
94. + NKT cells expand following administration of α-galactosylceramide-pulsed dendritic cells. Vox Sang. 83: 250-253.